Before starting a treatment plan, the specialist may also conduct basic tests to ensure youre a good fit
Evidence from a large health claims database in Switzerland
Oral GLP-1s (Rybelsus, Ozempic pill, Foundayo, and Wegovy) could suit patients with aversion to needles
Tirzepatide is a dual GIP/GLP-1 receptor agonist administered as a weekly subcutaneous injection, producing up to 20.9% weight loss at 72 weeks in Phase 3 trials
Potential considerations include: Injection site reactions Headaches or flushing sensations Temporary tingling or numbness in extremities Changes in blood glucose levels Important Precautions For both peptides, certain populations should exercise additional caution: Those with existing or past cancer concerns (GH may influence cell proliferation) People with diabetes or insulin sensitivity issues Individuals with active inflammatory or autoimmune conditions Women who are pregnant or breastfeeding A qualified healthcare provider should always supervise peptide therapy, with appropriate monitoring to ensure safety and efficacy
If a result seems absent, the problem is often the product, not your biology
